Novel drugs for suppressing endometriotic tissue target hormonal pathways via GnRH, estrogen and/or progesterone receptors, or modulate nonhormonal pathways including endometriosis-associated inflammation, cell proliferation, angiogenesis, adhesion and/or tissue invasion.